$CYTK
CYTOKINETICS INC

2015 Q1 Form 10-K Financial Statement

#000119312515081081 Filed on March 06, 2015

View on sec.gov

Income Statement

Concept 2015 Q1 2014 Q4 2013 Q4
Revenue $4.414M $21.76M $24.35M
YoY Change -44.68% -10.64% 1014.88%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $4.370M $4.560M $4.090M
YoY Change 2.58% 11.49% 7.07%
% of Gross Profit
Research & Development $8.956M $8.780M $13.82M
YoY Change -28.29% -36.47% 40.16%
% of Gross Profit
Depreciation & Amortization $145.0K $140.0K $80.00K
YoY Change 38.1% 75.0% -38.46%
% of Gross Profit
Operating Expenses $13.32M $13.34M $17.92M
YoY Change 6.67% -25.56% 31.09%
Operating Profit -$8.909M
YoY Change 1.58%
Interest Expense $40.00K $20.00K $100.0K
YoY Change 33.33% -80.0% 233.33%
% of Operating Profit
Other Income/Expense, Net $37.00K $0.00
YoY Change 42.31%
Pretax Income -$8.872M $8.440M $6.530M
YoY Change 1.46% 29.25% -156.98%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income 0.0% 0.0%
Net Earnings -$8.872M $8.443M $6.531M
YoY Change 1.46% 29.28% -157.01%
Net Earnings / Revenue -201.0% 38.8% 26.82%
Basic Earnings Per Share
Diluted Earnings Per Share -$229.3K $229.6K $218.8K
COMMON SHARES
Basic Shares Outstanding 38.67M shares 36.61M shares 29.50M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2015 Q1 2014 Q4 2013 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $107.9M $83.23M $77.73M
YoY Change 30.99% 7.08% 5.04%
Cash & Equivalents $22.55M $20.22M $20.16M
Short-Term Investments $85.32M $63.01M $57.57M
Other Short-Term Assets $2.000M $1.257M $1.605M
YoY Change 25.63% -21.68% -33.76%
Inventory
Prepaid Expenses
Receivables $1.000M $46.60M $0.00
Other Receivables $0.00 $200.0K $200.0K
Total Short-Term Assets $110.8M $131.1M $79.34M
YoY Change 28.77% 65.28% 3.81%
LONG-TERM ASSETS
Property, Plant & Equipment $1.551M $1.637M $1.221M
YoY Change 2.85% 34.07% 22.47%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $9.700M $0.00 $2.500M
YoY Change -50.26% -100.0%
Other Assets $200.0K $200.0K $127.0K
YoY Change 0.0% 57.48% 0.0%
Total Long-Term Assets $11.40M $1.837M $3.850M
YoY Change -46.27% -52.29% 242.53%
TOTAL ASSETS
Total Short-Term Assets $110.8M $131.1M $79.34M
Total Long-Term Assets $11.40M $1.837M $3.850M
Total Assets $122.2M $133.0M $83.19M
YoY Change 13.92% 59.84% 7.27%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.392M $1.361M $3.709M
YoY Change -17.58% -63.31% 85.26%
Accrued Expenses $3.981M $5.400M $8.272M
YoY Change -48.15% -34.72% 69.61%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $25.39M $23.86M $26.70M
YoY Change 28.26% -10.67% 275.85%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $12.70M $17.00M $2.000M
YoY Change 876.92% 750.0% 400.0%
Total Long-Term Liabilities $12.70M $0.00 $2.000M
YoY Change 876.92% -100.0% 400.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $25.39M $23.86M $26.70M
Total Long-Term Liabilities $12.70M $0.00 $2.000M
Total Liabilities $38.06M $40.90M $28.75M
YoY Change 80.4% 42.29% 285.03%
SHAREHOLDERS EQUITY
Retained Earnings -$506.1M -$497.2M -$482.6M
YoY Change 3.01% 3.03% 7.51%
Common Stock $39.00K $589.3M $31.00K
YoY Change 8.33% 1900903.23% 29.17%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $84.15M $92.06M $54.44M
YoY Change
Total Liabilities & Shareholders Equity $122.2M $133.0M $83.19M
YoY Change 13.92% 59.84% 7.27%

Cashflow Statement

Concept 2015 Q1 2014 Q4 2013 Q4
OPERATING ACTIVITIES
Net Income -$8.872M $8.443M $6.531M
YoY Change 1.46% 29.28% -157.01%
Depreciation, Depletion And Amortization $145.0K $140.0K $80.00K
YoY Change 38.1% 75.0% -38.46%
Cash From Operating Activities $34.36M -$8.130M -$12.43M
YoY Change -292.8% -34.59% 74.33%
INVESTING ACTIVITIES
Capital Expenditures $130.0K -$240.0K -$250.0K
YoY Change -60.96% -4.0% 316.67%
Acquisitions
YoY Change
Other Investing Activities -$31.96M $6.550M $6.060M
YoY Change 12.02% 8.09% -9.28%
Cash From Investing Activities -$32.09M $6.300M $5.810M
YoY Change 11.19% 8.43% -12.1%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $0.00
YoY Change -100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 70.00K 9.130M 7.520M
YoY Change -99.82% 21.41% 24966.67%
NET CHANGE
Cash From Operating Activities 34.36M -8.130M -12.43M
Cash From Investing Activities -32.09M 6.300M 5.810M
Cash From Financing Activities 70.00K 9.130M 7.520M
Net Change In Cash 2.340M 7.300M 900.0K
YoY Change -133.9% 711.11% -283.67%
FREE CASH FLOW
Cash From Operating Activities $34.36M -$8.130M -$12.43M
Capital Expenditures $130.0K -$240.0K -$250.0K
Free Cash Flow $34.23M -$7.890M -$12.18M
YoY Change -288.54% -35.22% 72.28%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2011Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
170000000 shares
CY2015Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
38674892 shares
CY2011Q2 cytk Gross Proceeds From Issuance Of Stock
GrossProceedsFromIssuanceOfStock
20100000
CY2012Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
9320176 shares
CY2012Q2 us-gaap Share Price
SharePrice
4.56
CY2012Q2 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
7894704 shares
CY2011Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
245000000 shares
CY2014Q2 dei Entity Public Float
EntityPublicFloat
174500000
CY2011Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
21.93
CY2011Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
585476 shares
CY2011Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1598408 shares
CY2011Q4 us-gaap Stockholders Equity
StockholdersEquity
48178000
CY2011Q4 us-gaap Line Of Credit
LineOfCredit
152000
CY2011Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
18833000
CY2012Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
18.96
CY2012Q4 us-gaap Share Price
SharePrice
4.56
CY2012Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
878726 shares
CY2012Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1790527 shares
CY2012Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
190193000
CY2012Q4 us-gaap Unrecognized Tax Benefits That Would Impact Effective Tax Rate
UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
4200000
CY2012Q4 us-gaap Income Tax Examination Penalties And Interest Accrued
IncomeTaxExaminationPenaltiesAndInterestAccrued
0
CY2012Q4 us-gaap Stockholders Equity
StockholdersEquity
70085000
CY2012Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
14907000
CY2012Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
190193000
CY2012Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
153193000
CY2012Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0
CY2012Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
25943000
CY2012Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
5101000
CY2012Q4 cytk Deferred Tax Assets Capitalized Research And Development
DeferredTaxAssetsCapitalizedResearchAndDevelopment
4932000
CY2012Q4 cytk Deferred Tax Assets Depreciation And Amortization
DeferredTaxAssetsDepreciationAndAmortization
1024000
CY2013Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
30681624 shares
CY2013Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
30681624 shares
CY2013Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
81500000 shares
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
15.15
CY2013Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2013Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2013Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
2161829 shares
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2449365 shares
CY2013Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
203863000
CY2013Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
1500000
CY2013Q4 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
22000
CY2013Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
20992000
CY2013Q4 us-gaap Accrued Vacation Current
AccruedVacationCurrent
778000
CY2013Q4 us-gaap Liabilities Current
LiabilitiesCurrent
26704000
CY2013Q4 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
1614000
CY2013Q4 us-gaap Unrecognized Tax Benefits That Would Impact Effective Tax Rate
UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
5000000
CY2013Q4 us-gaap Income Tax Examination Penalties And Interest Accrued
IncomeTaxExaminationPenaltiesAndInterestAccrued
0
CY2013Q4 us-gaap Common Stock Value
CommonStockValue
31000
CY2013Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2013Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
7000
CY2013Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3709000
CY2013Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-482597000
CY2013Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
8272000
CY2013Q4 us-gaap Stockholders Equity
StockholdersEquity
54442000
CY2013Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
115000
CY2013Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
83188000
CY2013Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
537001000
CY2013Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
697000
CY2013Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
14701000
CY2013Q4 us-gaap Other Employee Related Liabilities Current
OtherEmployeeRelatedLiabilitiesCurrent
93000
CY2013Q4 us-gaap Liabilities
Liabilities
28746000
CY2013Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
542000
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
20158000
CY2013Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1221000
CY2013Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
203863000
CY2013Q4 us-gaap Accounts Receivable Related Parties Current
AccountsReceivableRelatedPartiesCurrent
5000
CY2013Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
22213000
CY2013Q4 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
80200000
CY2013Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
144254000
CY2013Q4 us-gaap Long Term Investments
LongTermInvestments
2502000
CY2013Q4 us-gaap Assets
Assets
83188000
CY2013Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
57570000
CY2013Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0
CY2013Q4 us-gaap Interest Receivable
InterestReceivable
215000
CY2013Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
33043000
CY2013Q4 us-gaap Other Assets Current
OtherAssetsCurrent
1605000
CY2013Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
127000
CY2013Q4 us-gaap Assets Current
AssetsCurrent
79338000
CY2013Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
4946000
CY2013Q4 cytk Deferred Tax Assets Capitalized Research And Development
DeferredTaxAssetsCapitalizedResearchAndDevelopment
20702000
CY2013Q4 cytk Accrued Clinical And Preclinical Costs Current
AccruedClinicalAndPreclinicalCostsCurrent
4975000
CY2013Q4 cytk Deferred Tax Assets Depreciation And Amortization
DeferredTaxAssetsDepreciationAndAmortization
918000
CY2014Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
38659738 shares
CY2014Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
38659738 shares
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
3277489 shares
CY2014Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
81500000 shares
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
12.62
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
2140754 shares
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
15.17
CY2014Q4 us-gaap Share Price
SharePrice
8
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
12.64
CY2014Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2014Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2014Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
1270478 shares
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3297826 shares
CY2014Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
204900000
CY2014Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
16558000
CY2014Q4 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
52000
CY2014Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
20327000
CY2014Q4 us-gaap Accrued Vacation Current
AccruedVacationCurrent
915000
CY2014Q4 us-gaap Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
0
CY2014Q4 us-gaap Liabilities Current
LiabilitiesCurrent
23855000
CY2014Q4 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
2665000
CY2014Q4 us-gaap Unrecognized Tax Benefits That Would Impact Effective Tax Rate
UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
5100000
CY2014Q4 us-gaap Income Tax Examination Penalties And Interest Accrued
IncomeTaxExaminationPenaltiesAndInterestAccrued
0
CY2014Q4 us-gaap Common Stock Value
CommonStockValue
39000
CY2014Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2014Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-4000
CY2014Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1361000
CY2014Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-497243000
CY2014Q4 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
1860000
CY2014Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5400000
CY2014Q4 us-gaap Stockholders Equity
StockholdersEquity
92064000
CY2014Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
317000
CY2014Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
12380000
CY2014Q4 us-gaap Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
0
CY2014Q4 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
3626000
CY2014Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
132968000
CY2014Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
589272000
CY2014Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
421000
CY2014Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
17042000
CY2014Q4 us-gaap Other Employee Related Liabilities Current
OtherEmployeeRelatedLiabilitiesCurrent
110000
CY2014Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
3504000
CY2014Q4 us-gaap Line Of Credit
LineOfCredit
0
CY2014Q4 us-gaap Liabilities
Liabilities
40904000
CY2014Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
491000
CY2014Q4 cytk Number Of Financial Institutions
NumberOfFinancialInstitutions
3 Financial_Institution
CY2014Q4 cytk Deferred Tax Assets Depreciation And Amortization
DeferredTaxAssetsDepreciationAndAmortization
780000
CY2011Q2 cytk Issuance Cost Of Warrant
IssuanceCostOfWarrant
100000
CY2011Q2 cytk Preferred Stock Conversion Ratio
PreferredStockConversionRatio
0.001 pure
CY2012Q2 cytk Number Of Concurrent Public Offerings
NumberOfConcurrentPublicOfferings
2 PublicOffering
CY2012Q2 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
4000000
CY2012Q2 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
60000000
CY2014Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
3390000
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
20215000
CY2014Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1637000
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
2657000
CY2014Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
204900000
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
2642000
CY2014Q4 us-gaap Accounts Receivable Related Parties Current
AccountsReceivableRelatedPartiesCurrent
46646000
CY2014Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
21964000
CY2014Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
1553000
CY2014Q4 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
83200000
CY2014Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
148184000
CY2014Q4 us-gaap Long Term Investments
LongTermInvestments
0
CY2014Q4 us-gaap Assets
Assets
132968000
CY2014Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
63013000
CY2014Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0
CY2014Q4 us-gaap Interest Receivable
InterestReceivable
109000
CY2014Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss
AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
0
CY2014Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
34543000
CY2014Q4 us-gaap Other Assets Current
OtherAssetsCurrent
1257000
CY2014Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
200000
CY2014Q4 us-gaap Assets Current
AssetsCurrent
131131000
CY2014Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
6217000
CY2014Q4 cytk Deferred Tax Assets Capitalized Research And Development
DeferredTaxAssetsCapitalizedResearchAndDevelopment
15176000
CY2014Q4 cytk Accrued Clinical And Preclinical Costs Current
AccruedClinicalAndPreclinicalCostsCurrent
972000
CY2012Q2 cytk Proceeds From Issuance Or Sale Of Stock And Warrant
ProceedsFromIssuanceOrSaleOfStockAndWarrant
56000000
CY2013Q2 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.167 pure
CY2013Q2 cytk Number Of Issued Shares Of Common Stock Related To Cashless Exercise Of Warrants
NumberOfIssuedSharesOfCommonStockRelatedToCashlessExerciseOfWarrants
358460 shares
CY2012Q3 cytk Research Development Grant
ResearchDevelopmentGrant
500000
CY2013Q2 us-gaap Stockholders Equity Note Stock Split
StockholdersEquityNoteStockSplit
As a result of the one-for-six reverse stock split effected in June 2013, the conversion ratio for Series B convertible preferred stock changed from 1,000 shares of common stock per share of Series B convertible preferred stock to 166.67 shares of common stock per share of Series B convertible preferred stock.
CY2013Q2 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.167 pure
CY2010 cytk Research Development Grant
ResearchDevelopmentGrant
2800000
CY2010 cytk Period For Potential Treatment
PeriodForPotentialTreatment
P3Y
CY2013 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
5.32
CY2013 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.00 pure
CY2013 us-gaap Effective Income Tax Rate Reconciliation Tax Credits
EffectiveIncomeTaxRateReconciliationTaxCredits
-0.14 pure
CY2013 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-7718000
CY2013 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Upper Range Limit
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
11.1
CY2013 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
-0.04 pure
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
797629 shares
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
797629 shares
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
2000000 shares
CY2013 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
27275000 shares
CY2013 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.01 pure
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
12.55
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
117394 shares
CY2013 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
5.95
CY2013 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Lower Range Limit
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
4.02
CY2013 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.24
CY2013 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
-0.34 pure
CY2013 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
10197000 shares
CY2013 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
0.02 pure
CY2013 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
-623000
CY2013 us-gaap Revenue From Grants
RevenueFromGrants
94000
CY2013 us-gaap Repayments Of Secured Debt
RepaymentsOfSecuredDebt
0
CY2013 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
79434000
CY2013 us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
0
CY2013 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
1000
CY2013 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
0
CY2013 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
13700000
CY2013 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-11000
CY2013 us-gaap License And Services Revenue
LicenseAndServicesRevenue
3852000
CY2013 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-818000
CY2013 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
79000
CY2013 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
55000
CY2013 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
114000
CY2013 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-11000
CY2013 us-gaap Operating Income Loss
OperatingIncomeLoss
-33894000
CY2013 us-gaap Increase Decrease In Due From Related Parties Current
IncreaseDecreaseInDueFromRelatedPartiesCurrent
0
CY2013 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-33728000
CY2013 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
177000
CY2013 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-33717000
CY2013 us-gaap Gain On Sale Of Investments
GainOnSaleOfInvestments
0
CY2013 us-gaap Revenues
Revenues
30648000
CY2013 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
542000
CY2013 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-33717000
CY2013 us-gaap Net Income Loss
NetIncomeLoss
-33717000
CY2013 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
3523000
CY2013 us-gaap Interest And Debt Expense
InterestAndDebtExpense
-79000
CY2013 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
15092000
CY2013 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-1519000
CY2013 us-gaap Noncash Or Part Noncash Acquisition Fixed Assets Acquired1
NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1
193000
CY2013 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
0
CY2013 us-gaap Costs And Expenses
CostsAndExpenses
64542000
CY2013 us-gaap Restructuring Costs And Asset Impairment Charges
RestructuringCostsAndAssetImpairmentCharges
0
CY2013 us-gaap Investment Income Interest
InvestmentIncomeInterest
96000
CY2013 us-gaap Interest Paid
InterestPaid
0
CY2013 us-gaap Interest And Other Income
InterestAndOtherIncome
98000
CY2013 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3597000
CY2013 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-33717000
CY2013 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3597000
CY2013 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
0
CY2013 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
433000
CY2013 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
16201000
CY2013 us-gaap Interest Expense
InterestExpense
0
CY2013 us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
0
CY2013 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
49450000
CY2013 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
0
CY2013 us-gaap Restructuring Charges
RestructuringCharges
0
CY2013 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
5251000
CY2013 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2013 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
3306000
CY2013 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
0
CY2013 us-gaap Depreciation
Depreciation
400000
CY2013 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
14488000
CY2013 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
7450000
CY2013 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
13000
CY2013 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
0
CY2013 us-gaap Increase Decrease In Due To Related Parties Current
IncreaseDecreaseInDueToRelatedPartiesCurrent
-150000
CY2013 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
78444000
CY2013 us-gaap Share Based Compensation
ShareBasedCompensation
3597000
CY2013 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
0
CY2013 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
0
CY2013 us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
1656000
CY2013 us-gaap Other Preferred Stock Dividends And Adjustments
OtherPreferredStockDividendsAndAdjustments
0
CY2013 cytk Issuance Of Common Stock Employee Stock Purchase Plan Price Per Share
IssuanceOfCommonStockEmployeeStockPurchasePlanPricePerShare
3.66
CY2013 cytk Effective Income Tax Rate Reconciliation Net Operating Loss Expiration
EffectiveIncomeTaxRateReconciliationNetOperatingLossExpiration
0.01 pure
CY2013 cytk Share Based Compensation Arrangement By Share Based Payment Shares Available For Grant Award Options Exercised In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentSharesAvailableForGrantAwardOptionsExercisedInPeriodGross
0 shares
CY2013 cytk Stock Issued During Period Value New Issues To Related Party
StockIssuedDuringPeriodValueNewIssuesToRelatedParty
7450000
CY2013 cytk Proceeds From Draw Down Of Committed Equity Financing Facilities And At Market Facility Net Of Issuance Costs
ProceedsFromDrawDownOfCommittedEquityFinancingFacilitiesAndAtMarketFacilityNetOfIssuanceCosts
0
CY2013 cytk Shares Available For Grant Of Options Or Awards Options Forfeited Expired
SharesAvailableForGrantOfOptionsOrAwardsOptionsForfeitedExpired
117394 shares
CY2013 cytk License Revenues From Related Parties
LicenseRevenuesFromRelatedParties
17230000
CY2013 cytk Issuance Of Common Stock To Related Party For Cash Per Share
IssuanceOfCommonStockToRelatedPartyForCashPerShare
7.12
CY2013 cytk Issuance Of Common Stock To Related Party Issuance Costs
IssuanceOfCommonStockToRelatedPartyIssuanceCosts
21000
CY2013 cytk Effective Income Tax Rate Reconciliation Deferred Tax Assets Utilized Not Benefited
EffectiveIncomeTaxRateReconciliationDeferredTaxAssetsUtilizedNotBenefited
0.41 pure
CY2013 cytk Stock Issued During Period Value Exercise Of Warrants
StockIssuedDuringPeriodValueExerciseOfWarrants
5000
CY2013 cytk Research And Development Revenues From Related Parties
ResearchAndDevelopmentRevenuesFromRelatedParties
2019000
CY2013 cytk Proceeds And Payments From Stock Based Award And Warrants Net Of Issuance Costs
ProceedsAndPaymentsFromStockBasedAwardAndWarrantsNetOfIssuanceCosts
-7038000
CY2013 cytk Research And Development Grant And Other Revenues
ResearchAndDevelopmentGrantAndOtherRevenues
7547000
CY2013 cytk Effective Income Tax Rate Reconciliation State Apportionment
EffectiveIncomeTaxRateReconciliationStateApportionment
0.07 pure
CY2013 cytk Noncash Or Part Noncash Acquisition Fixed Assets Acquired Trade In Value
NoncashOrPartNoncashAcquisitionFixedAssetsAcquiredTradeInValue
81000
CY2013 cytk Increase Decrease In Noncash Or Part Noncash Acquisition Fixed Assets Acquired Through Accrued Liabilities
IncreaseDecreaseInNoncashOrPartNoncashAcquisitionFixedAssetsAcquiredThroughAccruedLiabilities
-2000
CY2014 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P6Y9M11D
CY2014 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
6.00
CY2014 dei Document Type
DocumentType
10-K
CY2014 dei Entity Registrant Name
EntityRegistrantName
CYTOKINETICS INC
CY2014 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2014 dei Trading Symbol
TradingSymbol
CYTK
CY2014 dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
CY2014 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2014 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.00 pure
CY2014 us-gaap Effective Income Tax Rate Reconciliation Tax Credits
EffectiveIncomeTaxRateReconciliationTaxCredits
-0.07 pure
CY2014 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-44843000
CY2014 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
As of the effective time of the reverse stock split, every six shares of the Company's issued and outstanding common stock were converted into one issued and outstanding share of common stock, without any change in par value per share.
CY2014 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
-0.01 pure
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
944831 shares
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
944831 shares
CY2014 us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%; MARGIN-TOP: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2"><b><i>Use of Estimates</i></b></font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</font></p> </div>
CY2014 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
35709000 shares
CY2014 dei Document Period End Date
DocumentPeriodEndDate
2014-12-31
CY2014 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.00 pure
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
39.74
CY2014 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y9M15D
CY2014 dei Amendment Flag
AmendmentFlag
false
CY2014 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2014 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2014
CY2014 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y9M4D
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
95980 shares
CY2014 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
8.80
CY2014 dei Entity Central Index Key
EntityCentralIndexKey
0001061983
CY2014 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.41
CY2014 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
-0.34 pure
CY2014 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2014 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
10067000 shares
CY2014 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div> <p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%; MARGIN-TOP: 18px"> <font style="FONT-FAMILY: Times New Roman" size="2"><b><i>Concentration of Credit Risk and Other Risks and Uncertainties</i></b></font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">Financial instruments that potentially subject the Company to concentrations of risk consist principally of cash and cash equivalents, investments and accounts receivable.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">The Company&#x2019;s cash, cash equivalents and investments are invested in deposits with three major financial institutions in the United States.&#xA0;Deposits in these banks may exceed the amount of insurance provided on such deposits. The Company has not experienced any realized losses on its deposits of cash, cash equivalents or investments.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">The economic turmoil in the United States in recent years, the extraordinary volatility in the stock markets and other current negative macroeconomic indicators could negatively impact the Company&#x2019;s ability to raise the funds necessary to support its business and may materially adversely affect its business, operating results and financial condition.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">The Company performs an ongoing credit evaluation of its strategic partners&#x2019; financial conditions and generally does not require collateral to secure accounts receivable from its strategic partners. The Company&#x2019;s exposure to credit risk associated with non-payment will be affected principally by conditions or occurrences within Amgen Inc. (&#x201C;Amgen&#x201D;) and Astellas Pharma Inc. (&#x201C;Astellas&#x201D;), its strategic partners. Approximately 10%, 63% and 55% of total revenues for the years ended December&#xA0;31, 2014, 2013 and 2012, respectively, were derived from Amgen. Accounts receivable due from Amgen were $1.6 million and zero at December&#xA0;31, 2014 and 2013, respectively. See also Note&#xA0;7, &#x201C;Related Party Transactions,&#x201D; regarding the collaboration agreement with Amgen. Approximately 69% and 34% of total revenues for the years ended December&#xA0;31, 2014 and 2013, respectively, were derived from Astellas. Accounts receivable due from Astellas were $45.0 million and zero at December&#xA0;31, 2014 and 2013, respectively. See also Note&#xA0;7, &#x201C;Related Party Transactions,&#x201D; regarding the collaboration agreement with Astellas.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">Drug candidates developed by the Company may require approvals or clearances from the U.S.&#xA0;Food and Drug Administration (&#x201C;FDA&#x201D;) or international regulatory agencies prior to commercialized sales. There can be no assurance that the Company&#x2019;s drug candidates will receive any of the required approvals or clearances. If the Company was to be denied approval or clearance or any such approval or clearance was to be delayed, it would have a material adverse impact on the Company.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%" align="justify"><font style="FONT-FAMILY: Times New Roman" size="2">The Company&#x2019;s operations and employees are located in the United States. In the year ended December&#xA0;31, 2014, 31% of the Company&#x2019;s revenues were received from entities located in the United States and 69% were received from a Japanese entity. In the year ended December&#xA0;31, 2013, 66% of the Company&#x2019;s revenues were received from entities located in the United States and 34% were received from a Japanese entity. In the year ended December&#xA0;31, 2012, all of the Company&#x2019;s revenues were received from entities located in the United States or from United States affiliates of foreign corporations.</font></p> </div>
CY2014 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
0.05 pure
CY2014 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1 Segment
CY2014 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2014 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
-96000
CY2014 us-gaap Revenue From Grants
RevenueFromGrants
75000
CY2014 us-gaap Repayments Of Secured Debt
RepaymentsOfSecuredDebt
0
CY2014 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
2800000
CY2014 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
107043000
CY2014 us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
0
CY2014 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
1000
CY2014 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
0
CY2014 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
1000000
CY2014 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-11000
CY2014 us-gaap License And Services Revenue
LicenseAndServicesRevenue
9836000
CY2014 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-274000
CY2014 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
0
CY2014 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
67000
CY2014 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
2000
CY2014 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-11000
CY2014 us-gaap Operating Income Loss
OperatingIncomeLoss
-14754000
CY2014 us-gaap Increase Decrease In Due From Related Parties Current
IncreaseDecreaseInDueFromRelatedPartiesCurrent
46641000
CY2014 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-14657000
CY2014 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
108000
CY2014 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-14646000
CY2014 us-gaap Gain On Sale Of Investments
GainOnSaleOfInvestments
6000
CY2014 us-gaap Revenues
Revenues
46940000
CY2014 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1104000
CY2014 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-14646000
CY2014 us-gaap Net Income Loss
NetIncomeLoss
-14646000
CY2014 us-gaap Investment Income Interest
InvestmentIncomeInterest
101000
CY2014 us-gaap Interest Paid
InterestPaid
0
CY2014 us-gaap Interest And Other Income
InterestAndOtherIncome
108000
CY2014 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3330000
CY2014 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-14646000
CY2014 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3330000
CY2014 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
0
CY2014 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
490000
CY2014 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
17399000
CY2014 us-gaap Interest Expense
InterestExpense
0
CY2014 us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
0
CY2014 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
44426000
CY2014 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
0
CY2014 us-gaap Restructuring Charges
RestructuringCharges
0
CY2014 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
57000
CY2014 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2014 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
3338000
CY2014 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
0
CY2014 us-gaap Depreciation
Depreciation
500000
CY2014 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
48949000
CY2014 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
48971000
CY2014 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
0
CY2014 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
0
CY2014 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-2865000
CY2014 us-gaap Interest And Debt Expense
InterestAndDebtExpense
0
CY2014 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-4049000
CY2014 us-gaap Noncash Or Part Noncash Acquisition Fixed Assets Acquired1
NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1
170000
CY2014 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
0
CY2014 us-gaap Costs And Expenses
CostsAndExpenses
61694000
CY2014 us-gaap Restructuring Costs And Asset Impairment Charges
RestructuringCostsAndAssetImpairmentCharges
0
CY2014 us-gaap Adjustments To Additional Paid In Capital Stock Split
AdjustmentsToAdditionalPaidInCapitalStockSplit
139000
CY2014 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
17268000
CY2014 cytk Effective Income Tax Rate Reconciliation State Apportionment
EffectiveIncomeTaxRateReconciliationStateApportionment
0.28 pure
CY2014 cytk Noncash Or Part Noncash Acquisition Fixed Assets Acquired Trade In Value
NoncashOrPartNoncashAcquisitionFixedAssetsAcquiredTradeInValue
0
CY2014 us-gaap Increase Decrease In Due To Related Parties Current
IncreaseDecreaseInDueToRelatedPartiesCurrent
0
CY2014 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
104098000
CY2014 us-gaap Share Based Compensation
ShareBasedCompensation
3330000
CY2014 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
0
CY2014 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
336000
CY2014 us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
-2178000
CY2014 us-gaap Other Preferred Stock Dividends And Adjustments
OtherPreferredStockDividendsAndAdjustments
0
CY2014 cytk Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice
6
CY2014 cytk Issuance Of Common Stock Employee Stock Purchase Plan Price Per Share
IssuanceOfCommonStockEmployeeStockPurchasePlanPricePerShare
3.38
CY2014 cytk Non Cancelable Lease Expiration Year
NonCancelableLeaseExpirationYear
2018
CY2014 cytk Effective Income Tax Rate Reconciliation Net Operating Loss Expiration
EffectiveIncomeTaxRateReconciliationNetOperatingLossExpiration
0.02 pure
CY2014 cytk Share Based Compensation Arrangement By Share Based Payment Shares Available For Grant Award Options Exercised In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentSharesAvailableForGrantAwardOptionsExercisedInPeriodGross
0 shares
CY2014 cytk Proceeds From Draw Down Of Committed Equity Financing Facilities And At Market Facility Net Of Issuance Costs
ProceedsFromDrawDownOfCommittedEquityFinancingFacilitiesAndAtMarketFacilityNetOfIssuanceCosts
0
CY2014 cytk Non Cancelable Lease Additional Extension Period
NonCancelableLeaseAdditionalExtensionPeriod
P3Y
CY2014 cytk Stock Issued During Period Value Securities Purchase Agreement
StockIssuedDuringPeriodValueSecuritiesPurchaseAgreement
37492000
CY2014 cytk Percentage Of Income Tax Positions Likely To Be Realized
PercentageOfIncomeTaxPositionsLikelyToBeRealized
0.50 pure
CY2014 cytk Shares Available For Grant Of Options Or Awards Options Forfeited Expired
SharesAvailableForGrantOfOptionsOrAwardsOptionsForfeitedExpired
95980 shares
CY2014 cytk License Revenues From Related Parties
LicenseRevenuesFromRelatedParties
0
CY2014 cytk Fractional Shares From Reverse Stock Split Share
FractionalSharesFromReverseStockSplitShare
0 shares
CY2014 cytk Cash Requirements Term
CashRequirementsTerm
P12M
CY2014 cytk Effective Income Tax Rate Reconciliation Deferred Tax Assets Utilized Not Benefited
EffectiveIncomeTaxRateReconciliationDeferredTaxAssetsUtilizedNotBenefited
0.07 pure
CY2014 cytk Stock Issued During Period Value Exercise Of Warrants
StockIssuedDuringPeriodValueExerciseOfWarrants
6000
CY2014 cytk Research And Development Revenues From Related Parties
ResearchAndDevelopmentRevenuesFromRelatedParties
19538000
CY2014 cytk Proceeds And Payments From Stock Based Award And Warrants Net Of Issuance Costs
ProceedsAndPaymentsFromStockBasedAwardAndWarrantsNetOfIssuanceCosts
22000
CY2014 cytk Research And Development Grant And Other Revenues
ResearchAndDevelopmentGrantAndOtherRevenues
17566000
CY2014 cytk Research And Development Federal Tax Credit Carryforwards Expiration Date Year
ResearchAndDevelopmentFederalTaxCreditCarryforwardsExpirationDateYear
2021
CY2014 cytk Stock Issued During Period Value New Issues To Collaborative Partner
StockIssuedDuringPeriodValueNewIssuesToCollaborativePartner
9102000
CY2014 cytk Issuance Of Common Stock To Collaborative Partner For Cash Per Share
IssuanceOfCommonStockToCollaborativePartnerForCashPerShare
4.9
CY2014 cytk Issuance Of Common Stock To Collaborative Partner Issuance Costs
IssuanceOfCommonStockToCollaborativePartnerIssuanceCosts
8000
CY2014 cytk Increase Decrease In Noncash Or Part Noncash Acquisition Fixed Assets Acquired Through Accrued Liabilities
IncreaseDecreaseInNoncashOrPartNoncashAcquisitionFixedAssetsAcquiredThroughAccruedLiabilities
27000
CY2012 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.00 pure
CY2012 us-gaap Effective Income Tax Rate Reconciliation Tax Credits
EffectiveIncomeTaxRateReconciliationTaxCredits
-0.19 pure
CY2012 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-33438000
CY2012 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
-0.06 pure
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
403108 shares
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
403108 shares
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
416667 shares
CY2012 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
18107000 shares
CY2012 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.01 pure
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
17.00
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
210989 shares
CY2012 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
6.14
CY2012 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.30
CY2012 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
-0.34 pure
CY2012 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
14866000 shares
CY2012 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
0.00 pure
CY2012 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
-401000
CY2012 us-gaap Revenue From Grants
RevenueFromGrants
1308000
CY2012 us-gaap Repayments Of Secured Debt
RepaymentsOfSecuredDebt
152000
CY2012 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
2139000
CY2012 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
92788000
CY2012 us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
-196000
CY2012 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
1000
CY2012 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
0
CY2012 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
21100000
CY2012 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
15000
CY2012 us-gaap License And Services Revenue
LicenseAndServicesRevenue
0
CY2012 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
320000
CY2012 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
2000
CY2012 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
65000
CY2012 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
15000
CY2012 us-gaap Operating Income Loss
OperatingIncomeLoss
-40457000
CY2012 us-gaap Increase Decrease In Due From Related Parties Current
IncreaseDecreaseInDueFromRelatedPartiesCurrent
-10000
CY2012 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-40355000
CY2012 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
87000
CY2012 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-40370000
CY2012 us-gaap Gain On Sale Of Investments
GainOnSaleOfInvestments
0
CY2012 us-gaap Revenues
Revenues
7559000
CY2012 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
125000
CY2012 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-41677000
CY2012 us-gaap Net Income Loss
NetIncomeLoss
-40370000
CY2012 us-gaap Increase Decrease In Due To Related Parties Current
IncreaseDecreaseInDueToRelatedPartiesCurrent
138000
CY2012 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
63900000
CY2012 us-gaap Investment Income Interest
InvestmentIncomeInterest
83000
CY2012 us-gaap Interest Paid
InterestPaid
3000
CY2012 us-gaap Interest And Other Income
InterestAndOtherIncome
89000
CY2012 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3783000
CY2012 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
13761000
CY2012 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-40370000
CY2012 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3783000
CY2012 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
0
CY2012 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
591000
CY2012 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
0
CY2012 us-gaap Interest Expense
InterestExpense
3000
CY2012 us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
12318000
CY2012 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
35643000
CY2012 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
0
CY2012 us-gaap Restructuring Charges
RestructuringCharges
-56000
CY2012 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-3926000
CY2012 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2012 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
3375000
CY2012 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
0
CY2012 us-gaap Depreciation
Depreciation
600000
CY2012 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
58327000
CY2012 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
43677000
CY2012 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
2000
CY2012 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
0
CY2012 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
2098000
CY2012 us-gaap Interest And Debt Expense
InterestAndDebtExpense
2000
CY2012 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-28815000
CY2012 us-gaap Noncash Or Part Noncash Acquisition Fixed Assets Acquired1
NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1
116000
CY2012 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
0
CY2012 us-gaap Costs And Expenses
CostsAndExpenses
48016000
CY2012 us-gaap Restructuring Costs And Asset Impairment Charges
RestructuringCostsAndAssetImpairmentCharges
-56000
CY2012 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
12429000
CY2012 us-gaap Share Based Compensation
ShareBasedCompensation
3783000
CY2012 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
0
CY2012 us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
690000
CY2012 us-gaap Other Preferred Stock Dividends And Adjustments
OtherPreferredStockDividendsAndAdjustments
1307000
CY2012 cytk Issuance Of Common Stock Employee Stock Purchase Plan Price Per Share
IssuanceOfCommonStockEmployeeStockPurchasePlanPricePerShare
4.32
CY2012 cytk Effective Income Tax Rate Reconciliation Net Operating Loss Expiration
EffectiveIncomeTaxRateReconciliationNetOperatingLossExpiration
0.02 pure
CY2012 cytk Proceeds From Draw Down Of Committed Equity Financing Facilities And At Market Facility Net Of Issuance Costs
ProceedsFromDrawDownOfCommittedEquityFinancingFacilitiesAndAtMarketFacilityNetOfIssuanceCosts
2820000
CY2012 cytk Stock Issued During Period Value Securities Purchase Agreement
StockIssuedDuringPeriodValueSecuritiesPurchaseAgreement
29916000
CY2012 cytk Shares Available For Grant Of Options Or Awards Options Forfeited Expired
SharesAvailableForGrantOfOptionsOrAwardsOptionsForfeitedExpired
210989 shares
CY2012 cytk License Revenues From Related Parties
LicenseRevenuesFromRelatedParties
0
CY2012 cytk Issuance Cost Of Warrant
IssuanceCostOfWarrant
984000
CY2012 cytk Effective Income Tax Rate Reconciliation Deferred Tax Assets Utilized Not Benefited
EffectiveIncomeTaxRateReconciliationDeferredTaxAssetsUtilizedNotBenefited
0.56 pure
CY2012 cytk Research And Development Revenues From Related Parties
ResearchAndDevelopmentRevenuesFromRelatedParties
4177000
CY2012 cytk Proceeds And Payments From Stock Based Award And Warrants Net Of Issuance Costs
ProceedsAndPaymentsFromStockBasedAwardAndWarrantsNetOfIssuanceCosts
336000
CY2012 cytk Research And Development Grant And Other Revenues
ResearchAndDevelopmentGrantAndOtherRevenues
3382000
CY2012 cytk Effective Income Tax Rate Reconciliation State Apportionment
EffectiveIncomeTaxRateReconciliationStateApportionment
0.00 pure
CY2012 cytk Noncash Or Part Noncash Acquisition Fixed Assets Acquired Trade In Value
NoncashOrPartNoncashAcquisitionFixedAssetsAcquiredTradeInValue
0
CY2012 cytk Adjustments To Additional Paid In Capital Issuance Of Convertible Preferred Stock
AdjustmentsToAdditionalPaidInCapitalIssuanceOfConvertiblePreferredStock
12318000
CY2012 cytk Increase Decrease In Noncash Or Part Noncash Acquisition Fixed Assets Acquired Through Accrued Liabilities
IncreaseDecreaseInNoncashOrPartNoncashAcquisitionFixedAssetsAcquiredThroughAccruedLiabilities
37000
CY2013Q1 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-0.53
CY2013Q1 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.53
CY2013Q1 us-gaap Sales Revenue Net
SalesRevenueNet
821000
CY2013Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-12619000
CY2013Q1 us-gaap Net Income Loss
NetIncomeLoss
-12619000
CY2014Q1 us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
-0.27
CY2014Q1 us-gaap Sales Revenue Net
SalesRevenueNet
7979000
CY2014Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-8744000
CY2014Q1 us-gaap Net Income Loss
NetIncomeLoss
-8744000
CY2012Q2 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
32100000
CY2013Q2 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-0.58
CY2013Q2 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.58
CY2013Q2 us-gaap Sales Revenue Net
SalesRevenueNet
1009000
CY2013Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-15041000
CY2013Q2 us-gaap Net Income Loss
NetIncomeLoss
-15041000
CY2014Q2 us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
-0.23
CY2014Q2 us-gaap Sales Revenue Net
SalesRevenueNet
7788000
CY2014Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-8374000
CY2014Q2 us-gaap Net Income Loss
NetIncomeLoss
-8374000
CY2013Q3 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-0.43
CY2013Q3 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.43
CY2013Q3 us-gaap Sales Revenue Net
SalesRevenueNet
4469000
CY2013Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-12588000
CY2013Q3 us-gaap Net Income Loss
NetIncomeLoss
-12588000
CY2014Q3 us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
-0.16
CY2014Q3 us-gaap Sales Revenue Net
SalesRevenueNet
9415000
CY2014Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-5971000
CY2014Q3 us-gaap Net Income Loss
NetIncomeLoss
-5971000
CY2013Q4 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
0.21
CY2013Q4 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
0.22
CY2013Q4 us-gaap Sales Revenue Net
SalesRevenueNet
24349000
CY2013Q4 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
6531000
CY2013Q4 us-gaap Net Income Loss
NetIncomeLoss
6531000
CY2014Q4 us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
0.23
CY2014Q4 us-gaap Sales Revenue Net
SalesRevenueNet
21758000
CY2014Q4 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
8443000
CY2014Q4 us-gaap Net Income Loss
NetIncomeLoss
8443000

Files In Submission

Name View Source Status
0001193125-15-081081-index-headers.html Edgar Link pending
0001193125-15-081081-index.html Edgar Link pending
0001193125-15-081081.txt Edgar Link pending
0001193125-15-081081-xbrl.zip Edgar Link pending
cytk-20141231.xml Edgar Link completed
cytk-20141231.xsd Edgar Link pending
cytk-20141231_cal.xml Edgar Link unprocessable
cytk-20141231_def.xml Edgar Link unprocessable
cytk-20141231_lab.xml Edgar Link unprocessable
cytk-20141231_pre.xml Edgar Link unprocessable
d828167d10k.htm Edgar Link pending
d828167dex1040.htm Edgar Link pending
d828167dex231.htm Edgar Link pending
d828167dex311.htm Edgar Link pending
d828167dex312.htm Edgar Link pending
d828167dex321.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
Financial_Report.xlsx Edgar Link pending
g828167ex10_40pg136.jpg Edgar Link pending
g828167g88o03.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending